Added to YB: 2026-08-27
Pitch date: 2026-08-25
DMP.DE [neutral]
Dermapharm Holding SE
Author Info
Lux Opes Research covers European companies. Lots of them. Sign up for the newsletter.
Company Info
Dermapharm Holding SE, together with its subsidiaries, manufactures and sells off-patent branded pharmaceutical products in Germany, Italy, France, Austria, Switzerland, Spain, Portugal, the Netherlands, Croatia, Poland, Ukraine, the United States, and China.
Market Cap
EUR 2.0B
Pitch Price
N/A
Price Target
N/A
Dividend
N/A
EV/EBITDA
8.52
P/E
14.36
EV/Sales
2.43
Sector
Pharmaceuticals
Category
growth
Dermapharm (DMP Germany): Branded Pharma growth lifts margins despite uneven demand elsewhere
DMP.DE (earnings): Solid H1; margin story over revenue. Rev +2.9% to €591.0m but adj EBITDA +10.3% to €163.2m, margin +185bp to 27.6%. Branded Pharma (largest/most profitable) drove it: rev €321.9m +11.6%, EBITDA €137.0m +8.4%, led by allergology, international, Mucos (consolidated Jan, expands OTC pain/inflammation). Other Healthcare rev -1.4% (€177.4m, weak Anton Hübner/cannabis) but EBITDA +12.7% on lower costs/FX. axicorp deliberately shrinking Parallel Import: rev -14%, EBITDA loss narrowed to -€0.3m from -€1.6m. FY2026 guidance reaffirmed: rev €1.182-1.218bn, adj EBITDA €331-341m; H2 helped by seasonal allergy, international, Arkopharma recovery. Growth increasingly Branded Pharma-concentrated = higher-quality earnings mix.
Read full article (2 min)